Six at a Time Epclusa® is the first all-oral drug to treat adults with chronic HCV infection from genotypes 1 to 6. Read More Novel Technologies FVII Gene Therapy Trial in Dogs; New FIX and HCV Drugs An update on FVII gene therapy and more. Read More Novel Technologies FDA in Action Updates on Daklinza, Technivie, and the ACE910 trial Read More Novel Technologies Recognizing Great Clinical Work NHF is committed to the training and support of clinician-researchers in hematology. Read More Researcher Profiles Announcing JGP Fellowship Recipients NHF awarded 5 JGP Fellowships in 2014. Read More Researcher Profiles Home Stretch There are times when less really is more. With the June 6, 2014, US Food and Drug Administration (FDA) approval... Read More Novel Technologies Wave of Progress Progress. For years, the bleeding disorders community has been waiting for meaningful progress for a greater understanding of hemophilia, for... Read More Novel Technologies, Hemophilia A&B CDC’s Inhibitor Risk Study A six-year study by the US Centers for Disease Control and Prevention (CDC) of patients with inhibitors, antibodies to infused... Read More Novel Technologies NHF-Shire Clinical Fellow Profile: Rachael Grace, MD, MMSc This interview was conducted with Rachael Grace, MD, MMSc, Director, Hematology Clinic, Boston Children’s Hospital. The fellowship was funded from... Read More Researcher Profiles NHF-Shire Clinical Fellow Profile: Brian Branchford, MD HemAware is conducting a series of interviews with recipients of the NHF-Shire Clinical Fellowship. It is funded through the generous... Read More Researcher Profiles NHF-Shire Clinical Fellow Profile: Salley Pels, MD This interview was conducted with Salley Pels, MD, assistant professor of pediatrics and associate medical director at the Yale Hemostasis... Read More Researcher Profiles FDA Approves New HIV Drug When the US Food and Drug Administration (FDA) approved Tivicay ® (dolutegravir), a new drug to treat HIV, in August... Read More Research & Treatment, HIV Load More
